Virtual Library
Start Your Search
Veysel Gökçek
Author of
-
+
P1.09 - Pathology (Not CME Accredited Session) (ID 941)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.09-06 - The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience. (ID 12506)
16:45 - 18:00 | Author(s): Veysel Gökçek
- Abstract
Background
PD-L1 testing have become the new standard of care for patient diagnosis in advance Non-Small Cell Lung Carcinoma (NSCLC). NSCLC also is characterized by driver mutations in epidermal growth factor receptor (EGFR), alterations anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). This study aimed to evaluate and to compare with immunotherapy related biomarker PD-L1 and driver mutations biomarkers (EGFR, ALK, and ROS1) in Turkish patients with NSCLC retrospectively. PD-L1 positivity also was examined whether related to some clinico-pathological parameters in NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
A retrospective cohort composed of 650 consecutive patients diagnosis with NSCLC were tested for PD-L1 between November of 2016 and February of 2018. PD-L1 immunostaining was performed using and 22c3 (DAKO platform) or SP263 (Ventana platform). Pathology report were reviewed to collect patient demographic data, smoking status, tumor sup-types, and specimen types. For EGFR mutational analysis were examined using a real time assay (The cobas v2 ® EGFR Mutation Test). ALK and ROS1 translocations were evaluated by IHC + FISH method. For statistical analysis Pearson chi -square test was used.
4c3880bb027f159e801041b1021e88e8 Result
TABLE I
Parameter
PD-L1 status
Statistic
total
<1%
1-49%
≥50%
P-value (Pearson
Chi-Square)Age
≤60
282 (44.4%)
80 (28.4%)
110 (39.0%)
92 (32.6%)
0.070
>60
353 (55.6%)
113 (32.0%)
154 (43.6%)
86 (24.4%)
Gender
female
140 (22.0%)
46 (32.9%)
65 (46.4%)
29 (20.7%)
0.090
male
495 (78.0%)
147 (29.7%)
199 (40.2%)
149 (30.0%)
Smoking
no
77 (14.4%)
27 (35.1%)
37 (48.1%)
13 (16.9%)
0.072
yes
456 (85.6%)
143 (31.4%)
179 (39.3%)
134 (29.4%)
Pathology
adenoca
404 (63.8%)
134 (33.2%)
171 (42.3%)
99 (24.5%)
0.018
non-adenoca
229 (36.2%)
59 (25.8%)
91 (39.7%)
79 (34.5%)
EGFR status
wild type
429 (90.7%)
120 (28.0%)
179 (41.0%)
130 (30.3%)
0.002
exon 19
26 (5.5%)
17 (65.4%)
7 (26.9%)
2 (7.7%)
exon 21
13 (2.7%)
6 (46.2%)
6 (46.2%)
1 (7.7%)
others
5 (1.1%)
2 (40.0%)
1 (20.0%)
2 (40.0%)
ALK status
negative
414 (94.7%)
116 (28.0%)
177 (42.8%)
121 (29.2%)
0.890
positive
23 (5.3%)
6 (26.1%)
11 (47.8%)
6 (26.1%)
ROS1 status
negative
412 (97.6%)
116 (28.2%)
179 (43.4%)
117 (28.4%)
0.251
positive
10 (2.4%)
1 (10.0%)
4 (40.0%)
5 (50.0%)
Clinico-pathological characteristics of NSCLC patients (n=650) and their relationships with PD-L1 expression were presented on Table I.
8eea62084ca7e541d918e823422bd82e Conclusion
This is the first study to compare PD-L1 expression with clinico-pathological parameters in Turkish NSCLC patients (n=650).
The majority of Turkish patients were smokers (85.6%). Although there was no statistical significance between PD-L1 positivity and smoking status, smoker patients showed more PD-L1 high tumor proportion score (H-TPS = ≥50%) than non-smoker patients; 29.4% to 16.9% respectively.
The majority of patients were Adenocarcinoma patients (63.8%).
PD-L1 positivity was higher in Non-adenocarcinoma patients than Adenocarcinomas (p=0.018).
This study demonstrated that PD-L1 positivity in lung adenocarcinoma, was strongly associated with EGFR wild-type status (p=0.002) which was parallel to literature.
There was no correlation between ALK and ROS1 translocation with PD-L1 status.
6f8b794f3246b0c1e1780bb4d4d5dc53